U.S. market Closed. Opens in 5 hours 10 minutes

ELVN | Enliven Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/AN/A
Cost of Revenue297.00K622.00K99.00K97.00K33.00KN/A
Gross Profit-297.00K-622.00K-99.00K-97.00K-33.00KN/A
Operating Expenses83.53M38.79M24.76M9.32M24.08M10.68M
Selling, General & Admin17.66M7.77M4.29M1.08M5.07M2.44M
Research & Development64.57M31.02M20.47M8.24M19.01M8.24M
Other Operating Expenses1.30MN/AN/A-9.68MN/AN/A
Operating Income-83.53M-38.79M-24.76M-9.32M-24.12M-10.68M
Other Expenses / Income11.95M1.13M22.00K-9.65M653.00K-660.00K
Before Tax Income-71.58M-37.66M-24.74M-18.97M-23.46M-11.34M
Income Tax Expenses1.30M88.00K-22.00K-31.00K653.00KN/A
Net Income-71.58M-37.75M-24.72M-18.93M-23.46M-11.34M
Interest ExpensesN/A-1.22MN/AN/AN/AN/A
Basic Shares Outstanding35.55M3.12M2.31M3.48M4.32M9.44M
Diluted Shares Outstanding35.55M3.12M2.31M3.48M4.32M9.44M
EBITDA-81.93M-38.58M-24.65M-9.27M-24.08M-11.34M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-70.28M-38.88M-24.74M-18.97M-22.81M-11.34M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙